Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

BACKGROUND: Treatment options for triple-negative breast cancer remain limited. Activation of the PI3K pathway via loss of PTEN and/or INPP4B is common. Buparlisib is an orally bioavailable, pan-class I PI3K inhibitor. We evaluated the safety and efficacy of buparlisib in patients with metastatic tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Garrido-Castro, Ana C., Saura, Cristina, Barroso-Sousa, Romualdo, Guo, Hao, Ciruelos, Eva, Bermejo, Begoña, Gavilá, Joaquin, Serra, Violeta, Prat, Aleix, Paré, Laia, Céliz, Pamela, Villagrasa, Patricia, Li, Yisheng, Savoie, Jennifer, Xu, Zhan, Arteaga, Carlos L., Krop, Ian E., Solit, David B., Mills, Gordon B., Cantley, Lewis C., Winer, Eric P., Lin, Nancy U., Rodon, Jordi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607628/
https://www.ncbi.nlm.nih.gov/pubmed/33138866
http://dx.doi.org/10.1186/s13058-020-01354-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607628/
https://www.ncbi.nlm.nih.gov/pubmed/33138866
http://dx.doi.org/10.1186/s13058-020-01354-y

Ejemplares similares